The trial will be conducted in the Democratic Republic of the Congo in partnership with Emergent BioSolutions.

Emergent BioSolutions Inc (EBS) reports a robust financial performance with a 9% revenue increase and significant debt reduction, despite challenges in Narcan sales.

November 6, 2024Emergent BioSolutions Inc. beats earnings expectations. Reported EPS is $1.37, expectations were $0.14.

Emergent BioSolutions' Q3 earnings report drives 20% surge in share price, reflecting market optimism. See why award a ...

On Thursday, Emergent Biosolutions Inc (EBS) stock saw a modest uptick, ending the day at $11 which represents a slight increase of $1.80 or 19.57% from the prior close of $9.2. The stock opened at ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

Wiles is co-chair at lobbying firm Mercury Public Affairs and has represented clients in the tobacco, junk food, insurance, ...

Emergent BioSolutions Inc. is heading into its next chapter — or “turnaround” phase, as its CEO describes it — after a strong ...